(917) 310-3371
Describe each symptom
Note dryness, burning, itching, discharge, bleeding, pain with sex, urinary urgency, recurrent urinary concerns, and what makes symptoms better or worse.
Vaginal estrogen therapy evaluation in NYC
Get a focused evaluation for dryness, burning, irritation, pain with sex, or menopause-related urinary symptoms before choosing a cream, insert, tablet, ring, nonhormonal option, or another next step.
Vaginal estrogen therapy evaluation
Vaginal symptoms can also come from infection, skin conditions, bleeding, pelvic floor problems, or another cause. The visit should confirm what is being treated.
What the visit can cover
The visit begins with the clinical question and the records that can change the next step.
Confirm the symptom pattern
The clinician separates likely genitourinary syndrome of menopause from infection, skin disease, pelvic-floor concerns, and other causes.
Review prior treatment
Bring nonhormonal moisturizers, lubricants, prescriptions, and any prior reactions or reasons a treatment was stopped.
Choose a formulation carefully
If local estrogen is appropriate, the clinician reviews the product form, instructions, expected follow-up, and current prescribing information.
Plan reassessment
Persistent pain, bleeding, discharge, urinary symptoms, or poor response may require an exam, testing, a changed plan, or referral.
How care works
Review medical history
Discuss menopause timing, surgeries, cancer history, unexplained bleeding, clotting or cardiovascular history, liver conditions, medicines, and prior estrogen use.
Confirm the likely cause
The clinician decides whether an exam, infection testing, cervical screening, urine testing, or referral is needed before treatment.
Select and monitor treatment
When vaginal estrogen is appropriate, the clinician uses the current product label and sets a follow-up plan. Nonhormonal care or another treatment may fit better.
Local vaginal estrogen is not the same as a general vaginal-symptom visit
Genitourinary syndrome of menopause can affect vaginal tissue, sexual comfort, and urinary symptoms as estrogen levels change. Local estrogen products deliver estrogen in the vaginal area, but the available forms are not interchangeable instructions for every patient.
Unexpected bleeding, new discharge, sores, pelvic pain, or symptoms that suggest infection should be evaluated rather than automatically treated as menopause. Vaginal estrogen does not replace cervical screening or clinician-collected HPV testing.
Patients with a history of hormone-sensitive cancer or complex gynecologic disease need an individualized decision. The clinician may coordinate with an oncologist or gynecologist before recommending treatment. No general webpage can replace that review.
Bleeding needs its own evaluation
Report bleeding after menopause or unexplained bleeding before starting treatment and while using it. Seek urgent care for severe bleeding, fainting, chest pain, trouble breathing, a severe allergic reaction, or other emergency symptoms.
Confirm the visit before expecting a prescription
Start with a women's health visit. The clinician confirms the diagnosis and whether Nao Medical can manage the treatment or should coordinate specialty care.
Clinic confirmation
Confirm the right Nao Medical clinic
The care team confirms the visit type and an eligible clinic before any product, procedure, or treatment-specific appointment.
Visit preparation
Bring a symptom and treatment timeline
Cycle or bleeding dates, symptom patterns, medicines, prior treatments, and relevant records help the clinician use the visit well.
Related care
Choose the related care that matches the question you want the clinician to address.
Menopause and perimenopause evaluation
Review vasomotor symptoms, sleep, cycles, treatment choices, and preventive needs together.
Women's health and GYN care
Get care for broader pelvic, discharge, birth-control, and preventive concerns.
Cervical cancer screening and Pap tests
Pap cytology and cervical screening remain a separate preventive service.
HPV testing
Review clinician-directed HPV testing, result interpretation, and follow-up.
Current official medical sources
Sources from FDA and ACOG were checked on August 1, 2026.
U.S. Food and Drug Administration
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
Current 2026 labeling changes and the need for individualized benefit-risk review.
Read the official sourceU.S. Food and Drug Administration
Menopause
Menopause symptoms, FDA-approved treatment options, and postmenopausal bleeding warning.
Read the official sourceAmerican College of Obstetricians and Gynecologists
Hormone Therapy for Menopause
Local versus systemic therapy, treatment selection, and ongoing review.
Read the official sourceU.S. Food and Drug Administration
Estring (estradiol vaginal system) Prescribing Information
Current product-specific vaginal estrogen labeling and administration information.
Read the official sourceU.S. Food and Drug Administration
FDA Approves First Generic Estradiol Vaginal Insert
FDA-approved local estradiol option for a menopause-related vaginal symptom.
Read the official sourceFrequently asked questions
The visit can review menopause-related vaginal dryness, burning, irritation, discomfort with sex, and some urinary symptoms. The clinician also checks whether infection, bleeding, a skin condition, or another cause needs different care.
No. Local vaginal estrogen is intended mainly for vaginal and related urinary symptoms. Systemic hormone therapy reaches the bloodstream and is used for other menopause symptoms. Product labels and individual risks differ.
Not every patient needs the same exam. Bleeding, discharge, pain, sores, screening history, treatment response, and uncertainty about the diagnosis can make an exam or testing important.
That decision requires individualized review. A clinician may recommend nonhormonal care first and may coordinate with the patient's oncologist or gynecologist before considering a local estrogen product.
Bleeding after menopause needs evaluation and should not be treated as routine dryness. Tell the clinician before starting therapy and report any bleeding that occurs during treatment.
Duration depends on the symptom, product, response, side effects, and medical history. The prescriber should review whether treatment is still needed and whether the current product remains appropriate.
No. Vaginal estrogen does not replace testing or treatment for yeast, bacterial vaginosis, sexually transmitted infections, urinary infection, or skin disease. Similar symptoms need the right diagnosis.
Start with the right evaluation
Vaginal symptoms can also come from infection, skin conditions, bleeding, pelvic floor problems, or another cause. The visit should confirm what is being treated.
Medical content checked against the sources above on August 1, 2026.
Health information notice
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.